Northern Trust Corp Cytom X Therapeutics, Inc. Transaction History

Northern Trust Corp

  • $600 Billion
  • Q3 2024

A detailed history of Northern Trust Corp transactions in Cytom X Therapeutics, Inc. stock. As of the latest transaction made, Northern Trust Corp holds 129,886 shares of CTMX stock, worth $129,886. This represents 0.0% of its overall portfolio holdings.

Number of Shares
129,886
Previous 131,027 0.87%
Holding current value
$129,886
Previous $159,000 3.77%
% of portfolio
0.0%
Previous 0.0%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024
SELL
$1.12 - $1.51 $1,277 - $1,722
-1,141 Reduced 0.87%
129,886 $153,000
Q2 2024

Aug 14, 2024
SELL
$1.21 - $5.13 $3,740 - $15,856
-3,091 Reduced 2.3%
131,027 $159,000
Q1 2024

May 14, 2024
SELL
$1.41 - $2.74 $1,669 - $3,244
-1,184 Reduced 0.88%
134,118 $292,000
Q4 2023

Feb 13, 2024
BUY
$1.07 - $1.55 $16,459 - $23,843
15,383 Added 12.83%
135,302 $209,000
Q3 2023

Nov 13, 2023
BUY
$1.26 - $1.87 $384 - $570
305 Added 0.25%
119,919 $154,000
Q2 2023

Aug 11, 2023
SELL
$1.41 - $1.92 $544 - $741
-386 Reduced 0.32%
119,614 $205,000
Q1 2023

May 15, 2023
BUY
$1.48 - $2.88 $11,203 - $21,801
7,570 Added 6.73%
120,000 $181,000
Q3 2022

Nov 14, 2022
SELL
$1.23 - $1.97 $63 - $102
-52 Reduced 0.05%
112,430 $163,000
Q2 2022

Aug 12, 2022
SELL
$1.53 - $2.89 $705,258 - $1.33 Million
-460,953 Reduced 80.38%
112,482 $206,000
Q1 2022

May 13, 2022
SELL
$2.67 - $4.68 $111,835 - $196,026
-41,886 Reduced 6.81%
573,435 $1.53 Million
Q4 2021

Feb 08, 2022
SELL
$3.87 - $7.39 $152,342 - $290,907
-39,365 Reduced 6.01%
615,321 $2.66 Million
Q3 2021

Nov 15, 2021
SELL
$4.32 - $6.43 $50,924 - $75,796
-11,788 Reduced 1.77%
654,686 $3.33 Million
Q2 2021

Aug 13, 2021
SELL
$6.33 - $9.91 $116,794 - $182,849
-18,451 Reduced 2.69%
666,474 $4.22 Million
Q1 2021

May 12, 2021
BUY
$6.6 - $9.0 $1.06 Million - $1.44 Million
160,374 Added 30.57%
684,925 $5.3 Million
Q4 2020

Feb 11, 2021
SELL
$6.47 - $7.9 $37,739 - $46,080
-5,833 Reduced 1.1%
524,551 $3.44 Million
Q3 2020

Nov 16, 2020
SELL
$6.55 - $8.83 $253,393 - $341,597
-38,686 Reduced 6.8%
530,384 $3.53 Million
Q2 2020

Aug 14, 2020
SELL
$7.4 - $14.64 $46,990 - $92,964
-6,350 Reduced 1.1%
569,070 $4.74 Million
Q1 2020

May 14, 2020
BUY
$3.61 - $8.6 $54,041 - $128,742
14,970 Added 2.67%
575,420 $4.41 Million
Q4 2019

Feb 14, 2020
BUY
$5.17 - $8.91 $8,944 - $15,414
1,730 Added 0.31%
560,450 $4.66 Million
Q3 2019

Nov 13, 2019
BUY
$7.38 - $12.25 $93,297 - $154,864
12,642 Added 2.32%
558,720 $4.12 Million
Q2 2019

Aug 13, 2019
BUY
$9.35 - $11.41 $37,942 - $46,301
4,058 Added 0.75%
546,078 $6.13 Million
Q1 2019

May 13, 2019
BUY
$9.5 - $19.16 $19,294 - $38,913
2,031 Added 0.38%
542,020 $5.83 Million
Q4 2018

Feb 12, 2019
SELL
$12.69 - $18.61 $5,367 - $7,872
-423 Reduced 0.08%
539,989 $8.15 Million
Q3 2018

Nov 14, 2018
BUY
$18.04 - $26.41 $1.83 Million - $2.67 Million
101,278 Added 23.06%
540,412 $10 Million
Q2 2018

Sep 18, 2018
SELL
$21.38 - $29.68 $49,195 - $68,293
-2,301 Reduced 0.52%
439,134 $10 Million
Q2 2018

Aug 14, 2018
BUY
$21.38 - $29.68 $2.53 Million - $3.51 Million
118,420 Added 36.66%
441,435 $10.1 Million
Q1 2018

May 09, 2018
SELL
$21.76 - $34.22 $3,633 - $5,714
-167 Reduced 0.05%
323,015 $9.19 Million
Q4 2017

Feb 14, 2018
SELL
$19.0 - $23.09 $120,251 - $146,136
-6,329 Reduced 1.92%
323,182 $6.82 Million
Q3 2017

Nov 13, 2017
BUY
$13.53 - $18.17 $4.46 Million - $5.99 Million
329,511
329,511 $5.99 Million

Others Institutions Holding CTMX

# of Institutions
68
Shares Held
50.4M
Call Options Held
112K
Put Options Held
8.3K
View Full List

About CytomX Therapeutics, Inc.

CTMX Quotes by TradingView
  • Ticker CTMX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 65,950,200
  • Market Cap $66M
  • Description
  • CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical...
More about CTMX
Track This Portfolio

Track Northern Trust Corp Portfolio

Follow Northern Trust Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

News

Stay updated on Northern Trust Corp with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email